MyMD Pharmaceuticals Inc (MYMD)
2.86
+0.30
(+11.72%)
USD |
NASDAQ |
Apr 24, 16:00
2.93
+0.07
(+2.45%)
After-Hours: 20:00
MyMD Pharmaceuticals Cash from Operations (TTM): -12.98M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -12.98M |
| September 30, 2023 | -13.30M |
| June 30, 2023 | -14.23M |
| March 31, 2023 | -13.88M |
| December 31, 2022 | -12.27M |
| Date | Value |
|---|---|
| September 30, 2022 | -14.83M |
| June 30, 2022 | -17.19M |
| March 31, 2022 | -20.38M |
| December 31, 2021 | -19.52M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-20.38M
Minimum
Mar 2022
-12.27M
Maximum
Dec 2022
-15.40M
Average
-14.23M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
| Acrivon Therapeutics Inc | -42.64M |
| Vincerx Pharma Inc | -40.45M |
| CEL-SCI Corp | -23.07M |
| AIM ImmunoTech Inc | -21.27M |
| IGC Pharma Inc | -6.19M |